Discontinued — last reported Q4 '25
Year-over-year, this metric declined by 84.6%, from $2.60M to $400.00K. Over 3 years (FY 2022 to FY 2025), HST — Restructuring expenses and asset impairments shows a downward trend with a -11.4% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
High levels suggest significant internal change or portfolio cleanup, which may temporarily depress earnings.
The combined impact of operational reorganization costs and non-cash asset write-downs within the Health and Science Tec...
Often used by analysts to adjust EBITDA to understand 'normalized' operating performance.
iex_segment_hst_restructuring_expenses_and_asset_impairments| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $100.00K | $100.00K | $17.20M | $600.00K | $300.00K | $2.70M | $1.50M | $2.10M | $500.00K | $1.10M | $1.70M | $2.60M | $11.40M | $700.00K | $0.00 | $400.00K |
| QoQ Change | — | +0.0% | >999% | -96.5% | -50.0% | +800.0% | -44.4% | +40.0% | -76.2% | +120.0% | +54.5% | +52.9% | +338.5% | -93.9% | -100.0% | — |
| YoY Change | — | — | — | — | +200.0% | >999% | -91.3% | +250.0% | +66.7% | -59.3% | +13.3% | +23.8% | >999% | -36.4% | -100.0% | -84.6% |